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Summary
Introduction: Recent developments have enabled associate to standard pancreaticoduodenectomy (DPC), vascular resections 
to increase resectability in pancreatic cancer.
Objectives: Analyze morbidity, mortality and survival of a consecutive series of patients with pancreatic cancer, in which a DPC 
with portal vein resection was performed, and compared it with a group of patients with standard DPC without venous resection.
Methodology: Consecutive series of 67 patients who underwent a DPC ought to pancreatic ductal adenocarcinoma, between 
January 2005 and January 2015.
Results: Standard resection (RV-) was performed in 49 cases, and a venous resection in another 18 patients (RV+). There were no 
significant differences in age (65 vs 68.9 years), ASA, or intraoperative transfusion. Duration of intervention was significantly lower 
in the RV- group (6.1 vs 6.7; p = 0.05). Morbidity grade III -IV was 14.2 % Clavien in the RV- group and 16.6 % in the RV + group 
(p = 0.87). There were no differences in hospital mortality (0 % vs 5.5%), or hospital stay (14.4 vs 15.2 days). The surgical margin 
involvement was more frequent in the RV+ group (18 % vs 50 % ; p = 0.003). One, 3 and 5 years survival was 77, 34 and 11% in 
the RV- group and 92, 23 and 8% in the group with venous resection.
Conclusions: DPC with venous resection can be performed with morbidity and mortality rates similar to standard DPC1. Survival 
shows no significant difference between the two groups.Venous resection may increase resectability in a selected group of patients 
with pancreatic adenocarcinoma.
Keywords: Pancreatic ductal adenocarcinoma, morbidity, mortality, pancreaticoduodenectomy
Resumen
Introducción: Los progresos recientes han permitido asociar a la duodenopancreatectomía cefálica estándar (DPC), resecciones 
vasculares para incrementar la resecabilidad en el cáncer de páncreas.
Objetivos: Analizar la morbi-mortalidad y supervivencia de una serie consecutiva de pacientes con cáncer de páncreas, en los que 
se realizó una DPC con resección de vena porta y compararla con un grupo de pacientes con DPC estándar sin resección venosa.
Material y métodos: Serie consecutiva de 67 pacientes intervenidos con adenocarcinoma ductal de páncreas, entre enero 2005 
y enero 2015.  
Resultados: En 49 casos se realizó una resección estándar (RV-) y en 18 pacientes, una resección venosa (RV+). No hubo 
diferencias significativas en la edad (65 vs 68,9 años), ASA, ni en la transfusión intraoperatoria. La duración de la intervención fue 
significativamente menor en el grupo RV- (6,1 vs 6,7; p= 0,05). La morbilidad grado III-IV de Clavien fue del 14,2% en el grupo RV- y 
del 16,6% en el grupo RV+ (p=0,87). No hubo diferencias en la mortalidad hospitalaria (0% vs 5,5%), ni en la estancia hospitalaria 
(14,4 vs 15,2 días). La afectación del margen quirúrgico fue más frecuente en el grupo RV+ (18% vs 50%; p=0,003). La supervi-
vencia al año, 3 y 5 años fue del 77, 34 y 11% en el grupo RV-,y del 92, 23 y 8% en el grupo con resección venosa.
Conclusiones: La DPC con resección venosa puede realizarse con tasas de morbi-mortalidad similares a la DPC estándar. La 
supervivencia no muestra diferencias significativas entre los dos grupos. La resección venosa puede aumentar la resecabilidad en 
un grupo seleccionado de pacientes con adenocarcinoma de páncreas.
Palabras clave: Adenocarcinoma ductal de páncreas, morbilidad, mortalidad, duodenopancreatectomía
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Introduction
Pancreatic cancer is the fourth leading cause of cancer 
deaths in the world, with more than 100,000 deaths in 
Europe in 2012 and an increasing incidence over the 
last years due to unknown reasons.1-5 Although curative 
resection followed by adjuvant chemotherapy is the 
therapeutic scheme offering the highest survival results, 
little progress has been made in terms of survival in the 
last decades. Distant metastases (hepatic, pulmonary or 
peritoneal) at diagnosis appear in 50% of patients, with 
an estimated survival of 6 8 months. Furthermore, only 
20 25% of patients are eligible for surgical resection, 
whereas venous infiltration by contiguity (portal vein, 
superior mesenteric vein, superior mesenteric artery, 
hepatic artery or celiac trunk) appears in approximately 
30% of the diagnosed cases and this situation is 
considered a contraindication to surgical resection, with 
a median survival of 4 11 months despite de use of new 
cytostatic agents.1,6,7,8,9 On the other hand, the median 
survival of patients undergoing surgical resection is of 
20 25 months, with a survival at 5 years of around 20% 
and a local recurrence rate of 60 70% in the first 18 
months after resection.7,10,11 These figures show the 
aggressive biological behaviour of pancreatic cancer 
and its great capacity both for distant dissemination 
and for loco regional invasion with lymphovascular and 
perineural infiltration.
For many years, the low surgical resection indexes have 
motivated continuous efforts to perform resection of locally 
advanced tumours with vascular resection techniques. 
The first attempts were done by Moore12 (USA) in 
1951 and Asada13 (Japan) in 1963, who performed a 
cephalic pancreaticoduodenectomy (CPD) with resection 
and reconstruction of the superior mesenteric vein. 
Later, in 1973, Fortner14 (USA) used the term “regional 
pancreatectomy” to describe a surgical resection 
including a total pancreatectomy, a radical regional 
lymphadenectomy, and a resection with reconstruction 
of the portal vein (type I resection) and/or the superior 
mesenteric artery (type II resection). These radical 
procedures were abandoned during decades due to their 
lack of impact on survival and their high morbi mortality, 
arguing that tumours affecting the venous wall were bigger, 
more aggressive and presented a worse prognostic. 
However, in the last years, progress in surgical technique 
and in perioperative care has been able to reduce 
perioperative mortality to less than 5%, allowing for a 
more radical approach of locally advanced pancreatic 
tumours with invasion of the portal vein (PV) and/or the 
superior mesenteric vein (SMV).4,15,16,17,18 As a result, a 
group of selected patients considered until recently as 
unresectable are now eligible for CPD with vascular 
resection, thus obtaining a higher survival as if treated 
only with chemoradiotherapy.17,19 Tumours of this group 
of patients have been defined as “borderline”, that is, 
tumours halfway between clearly resectable tumours 
without vascular invasion and locally advanced, technically 
unresectable tumours with massive mesenteric portal 
venous and/or arterial infiltration.1 The meta analysis 
published by Siriwardana in 2006 revealed a median 
survival of 13 months and a survival at 5 years of 5% of 
the patients with vascular resection.20 Two following meta 
analyses showed greater operative time and transfusion 
requirements for patients with vascular resection, but 
did not find any differences in postoperative morbility 
and mortality between patients undergoing a CPD 
with and without vascular resection.2,3 As for long term 
survival, recent studies showed that medium and long 
term survival of patients after vascular resection is 
similar to that of patients who did not undergo vascular 
resection and, more important, survival in this patients 
is significantly higher to that of patients who have not 
undergone any kind of surgical resection or who had a 
palliative enterobiliary bypass done.2,3,4
Because of these reasons, the American Joint 
Commission on Cancer (AJCC) modified its classification 
in 2002, staging the infiltration of the mesenteric portal 
vein confluence as T3 instead of T4, and the National 
Commission on Cancer (NCCN) included venous 
resection in its recommendations for cases of localized 
vascular infiltration if clear resection margins and an 
appropriate vascular reconstruction was possible.21 
There is total unanimity with respect to considering 
that this kind of interventions are most profitable when 
performed in hospitals with a high volume of patients. 
The coordinated multidisciplinary approach required to 
perform this surgery allows to modify the management 
of at least 25% of the patients with pancreatic cancer 
and to rescue many patients who were considered as 
unresectable until today.22
Despite all these promising results and recent 
recommendations, and probably due to its greater 
technical complexity, venous resection in pancreatic 
cancer has not been widely included in all hospitals. 
The two main reasons that explain why tumours with 
infiltration of the mesenteric portal vein confluence are still 
being considered as unresectable are, first, that venous 
resection is considered to have a significantly higher 
surgical morbility and mortality and, second, that this 
kind of tumours are assumed to have a more aggressive 
biology both locally and systemically, thus having a worse 
prognosis and a lower short and medium term survival 
which result in considering these patients at prohibitive 
surgical risk and low survival. Luckily, recent studies prove 
the contrary, and it is therefore necessary to introduce 
these surgical techniques in the management of patients 
with pancreatic cancer.
The present study formulates two hypotheses:
First hypothesis. Pancreaticoduodenectomy with 
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vascular resection of the mesenteric portal vein 
confluence can be performed with a rate of postoperative 
complications and mortality similar to that of standard 
pancreaticoduodenectomy without vascular resection. 
Second hypothesis. Patients who underwent a cephalic 
pancreaticoduodenectomy with venous resection 
present a medium and long term survival comparable 
to that of patients who underwent a standard 
pancreaticoduodenectomy without vascular resection.
The main objectives of the study were: 
1. To analyse postoperative mortality and morbility of 
patients with pancreatic cancer with infiltration of the portal 
vein and/or the superior mesenteric vein who underwent 
a pancreaticoduodenectomy with venous resection, 
and compare it with the morbi mortality of patients who 
underwent a CPD without vascular resection to evaluate 
if venous resection implies a greater surgical risk. 
2. To determine medium and long term survival in patients 
who underwent vascular resection and compare it with that of 
patients who undergo a standard pancreaticoduodenectomy 
without venous resection to determine if venous resection 
can increase long term survival in patients with pancreatic 
cancer with portal vein invasion. 
Material and methodology
Tumour extension and resectability
Between January 2005 and January 2015, a total of 125 
consecutive pancreaticoduodenectomies were performed 
and their data was prospectively entered in a data base. 
A final diagnosis of pancreatic ductal adenocarcinoma 
was established in 67 patients, who constitute the object 
of the present study. All patients were studied following 
a pre established diagnostic therapeutic protocol and 
evaluated by a multidisciplinary committee of pancreatic 
tumours made up by oncologists, gastroenterologists, 
radiologists, pathologists, radiotherapists and surgeons.
The preoperative diagnostic therapeutic management 
scheme consisted of:
· Analytical study with tumour markers (CEA; CA 
19.9).
· Radiologic evaluation: ultrasonography, three 
phase computerized axial tomography (CAT) of 
the pancreas, and magnetic resonance imaging.
· Endoscopic evaluation: upper endoscopy, 
endosonography, fine needle aspiration 
biopsy (FNAB), endoscopic retrograde 
cholangiopancreatography (ERCP).
· Endoscopic or transhepatic biliary drainage in 
cases of surgical delay >10 days.
· Cytological study.
· Assessment of resectability.
Inclusion and exclusion criteria
Inclusion criteria: Patients diagnosed with pancreatic 
ductal adenocarcinoma in the pancreatic head, with/
without extension to the rest of the pancreas, who 
underwent a total resection with curative intention.
Exclusion criteria:
1. Systemic dissemination (hepatic or pulmonary).
2. Peritoneal dissemination. 
3. Arterial vascular infiltration (celiac trunk, common 
hepatic artery or superior mesenteric artery).
Surgical technique
All interventions were performed by the same group 
of surgeons. Pancreaticoduodenectomy included 
antrectomy (Whipple). In those cases of diffuse tumours 
or a positive intraoperative biopsy of the surgical margin, 
a total pancreaticoduodenectomy with splenectomy was 
performed. Routine included a lymphadenectomy of the 
hepatoduodenal ligament, the hepatic artery, the celiac 
trunk, the interaortocaval space and the right lateral 
side of the superior mesenteric artery.23 In both groups, 
reconstruction was performed with a double loop Roux 
en Y and an end to side pancreaticojejunal anastomosis 
in two layers with or without a silicone stent depending 
on the diameter of the pancreatic duct. The bile duct was 
reconstructed with an end to side hepaticojejunostomy. 
Gastrojejunal anastomosis was antecolic as described 
by Hartel.24 All patients remained in the postoperative 
care unit for at least 24 hours. Octreotide was only 
administered to patients with a great risk of pancreatic 
fistula (pancreatic duct ≤1 mm or soft pancreas). Two 
abdominal drainages were used: a subhepatic drainage 
and one close to the pancreatic anastomosis.
Three types of vascular reconstruction were performed: 
1. Lateral suture of SMV or PV in cases of infiltration 
≤25% of vein circumference (Figures 1A and 1B).
2. Segmental resection with end to end anastomosis 
with autologous vein in cases with infiltration >50% of 
vein circumference (Figures 2A and 2B).
3. Replacement by a polytetrafluoroethylene (PTFE) 
prosthesis in a case with PV infiltration of 3 cm of length.
In those cases of venous segmental resection, the 
superior mesenteric artery (SMA) was clamped before 
the venous resection and during the vascular resection, 
in order to avoid swelling of the small intestine. Once the 
resection pieces had been extracted, the retroperitoneal 
margin of the SMA was painted with ink and the cutting 
area of the vein was marked to facilitate its identification 
by the pathologist.
Patients with lateral venous resection were given the usual 
dose of low molecular weight heparin. In those cases of 
venous segmental resection and replacement by a PTFE 
prosthesis, patients were given a dose of intravenous 
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Figure 1A: Illustration of the lateral resection of the portal veinables.
Figure 2A: Illustration of the segmental resection of 2 cm of portal vein with end 
to end vascular anastomosis.
Figure 1B: Surgical image of the lateral resection of the portal vein. 1. Portal vein 
with lateral resection and vascular suture; 2. Cava vein; 3. Common hepatic artery.
Figure 2B: Surgical image of the segmental resection of 2 cm of portal vein with 
end to end vascular anastomosis. 1. Portal vein; 2. End to end anastomosis; 3. 
Cut and clamped bile duct; 4. Common hepatic artery.
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sodium heparin at the moment of clamping the SMA. 
All patients with venous resection were monitored with 
hepatoportal Doppler 24 hours after surgery.
Drainages in the portal mesenteric resection group were 
removed according to the amylase determination in the 
drainage liquid after the third postoperative day. Prokinetic 
drugs were only administered to patients with delayed 
gastric emptying (DGE).
Definitions
Pancreatic fistula. Drain output on or after postoperative 
day 3, with an amylase content greater than 3 times 
the upper limit of normal serum amylase level. The type 
of pancreatic fistula was categorized according to the 
grades and criteria of the International Study Group on 
Pancreatic Surgery (ISGPS).25
Delayed gastric emptying (DGE). Need of a nasogastric 
tube during more than 3 days or its insertion after 
postoperative day 3, as well as the lack of oral tolerance 
after the first postoperative week.26
Biliary fistula. Drain output on or after postoperative day 
5, with a bilirubin content greater than 3 times the upper 
limit of normal serum bilirubin level. 
Perioperative variables
The study population consisted of consecutively 
operated patients, and their data were prospectively 
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entered in a pancreatic resection data base. Studied 
demographical variables included age, sex, operation 
time, intra and postoperative transfusion, intensive 
care unit (ICU) stay, mortality, morbility and hospital 
stay. Mortality and complications were followed up until 
hospital discharge or death of the patient. Postoperative 
complications were registered using the Clavien Dindo 
classification (Table I).28 Readmissions were registered 
up to the 30th day after hospital discharge.
Postoperative follow up and survival
All patients were evaluated by the Oncology Department 
and received the corresponding adjuvant treatment 
and oncologic follow up. During the first two years after 
surgery, patients attended the oncology consultation 
every 6 months for evaluation by means of abdominal 
CAT scans, analyses, and tumour markers. After the 
second year, controls took place yearly. The follow up 
included visits to the oncology and surgery consultation, 
retrieval of their medical history through the Balearic 
Department of Health, and phone calls. 
The median survival was calculated on the basis of 
patients’ median follow up. The control group in terms of 
survival consisted of a group of patients with a pancreatic 
head tumour with infiltration of the mesenteric portal vein 
confluence who did not undergo vascular resection 
because they were diagnosed before the introduction of 
the CPD vascular resection program. 
Histopathological examination
An intraoperative biopsy of the pancreatic and biliary 
margin was performed routinely. In those cases in which 
the intraoperative margin was positive, the solution 
was either to increase this margin or to conduct a total 
pancreatectomy. The pathological study included the 
analysis of histological type, degree of cell differentiation, 
tumour size, lymph node infiltration, perineural infiltration 
and lymphovascular invasion. Resection margins 
involvement was defined following the classification by the 
American Joint Committee on Cancer definitions 2010 
(AJCC) until 2014. The following margins were studied 
and painted with different colours for their histological 
examination: stomach, bile duct, pancreatic trasnsection, 
portal vein and superior mesenteric artery. (Figure 3).
After 2014, the Verbeke guidelines were applied, which 
consider resection as R0 if there is a minimum clearance 
of 1 mm (Figure 4).29
Statistical analysis
Results are presented as the median ± SE (CI 95%), 
range or percentage (%). The Kolmogorov Smirnov test 
was applied to guarantee a Gaussian distribution of 
results. Comparisons among groups were performed 
by using the independent samples t test, the analysis 
of variance (ANOVA) or the Mann Whitney test for 
continuous variables, and the chi square test or the 
Fisher’s exact test for categorical variables. Survival 
estimates were calculated with the Kaplan Meier method 
and comparisons among curves were analysed with 
the log rank test. Finally, to analyse the impact of some 
variables on survival, odds ratio were calculated adjusted 
with 95% confidence intervals (CI) by means of logistic 
regression. For all calculations, a value of p<0.05 was 
considered statistically significant. Statistical analysis 
were done using the software package SPSS® 16.0 for 
Windows (SPSS® Inc., Chicago, IL, USA).
Ethical considerations 
and confidential treatment of data
The management, communication and transfer of 
personal data of all participants took place according to 
the provisions of the corresponding Spanish legislation 
(Organic Law 15/1999, of 13th December, on the 
Protection of Data of a Personal Nature). Handling of data 
Table I: Clavien Dindo classification
Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endos-
copic and radiological interventions. Allowed regimens are drugs as antiemetics, antipyretics, analgetics, diuretics and 
electrolytes, and physiotherapy. This grade also includes wound infections opened at the bedside. 
Complication requiring pharmacological treatment with drugs other than such allowed for Grade I complications. 
Blood transfusions and total parenteral nutrition are also included. 
Complication requiring surgical, endoscopic or radiological intervention with local anaesthesia.
Complications requiring surgical, endoscopic or radiological intervention with general anaesthesia.
Life threatening complication requiring IC/ICU management (including central nervous system complications).
Single organ dysfunction (including dialysis).
Multi organ dysfunction.
Death of patient.
Grade Type of complication
Grade I
Grade II
Grade III a
Grade III b
Grade IV
IV a
IV b
Grade V
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Figure 3: Painted surgical resection margins.
1. Stomach; 2. Pancreas section; 3. Portal vein margin; 4. Sup. mesenteric artery 
margin; 5. Duodenum Jejunum
3 4 51 2
Figure 4: Axial slicing of pancreatoduodenectomy specimens. Image from 
Verbeke CS. Redefining resection margin status in pancreatic cancer. HBP 2009; 
11: 282 289.29
was totally confidential, and only the main researcher 
had access to codified information. All participants 
were informed of the study and signed, before joining 
it, an informed consent with detailed explanations of the 
interventions, the surgical technique and the possibility 
of postoperative complications. All doubts and questions 
arisen were answered by the surgeon responsible for 
the study. Patients were also informed that their decision 
would not affect the medical care received and that they 
could abandon the study at any point.
Results
The population of the study consisted of all patients 
diagnosed with pancreatic ductal adenocarcinoma who 
consecutively underwent a CPD with curative intention 
between January of 2005 and January of 2015.
Demographical data
The study group consists of 67 patients, from 
whom 49 (73.1%) underwent a CPD without venous 
resection (VR- group) and 18 patients (26,9%) a CPD 
with venous resection due to infiltration of the wall of 
the mesenteric portal vein confluence (VR+ group). 
Distribution by sex, age, histology and preoperative risk 
measured by ASA was homogeneous in both groups. 
Median age of the VR- group was 65 ± 1.6 years 
(range 53 80) and that of the VR+ group, of 68.9 ± 2.4 
years (range 47 80) (p=0.184) (Table II). A CPD was 
performed total on 65 patients and in two cases a total 
pancreatoduodenectomy was required due to a tumour 
with diffuse invasion of the pancreas. 
Intraoperative results
Global median operation time was of 6.2 hours in the VR- 
group and of 6.9 hours in the VR+ group (non significant 
difference). The intraoperative and postoperative 
transfusion median was greater in the VR+ group (0.8 
1.2 packed red blood cells) than in the VR- group (0.47 
1 packed red blood cells), but the difference was non 
significant (p=0.26). Operation time was significantly 
greater in the VR+ group (7.3 hours) than in the VR- 
group (6.1 hours) (p=0.05).
Type of venous resection
In 15 patients (83.5%), infiltration of the venous wall 
was smaller than 50% of the circumference, so it was 
possible to perform a lateral resection with primary 
reparation using 6/0 polypropylene without a vein patch. 
Two patients presented infiltration greater than 50% 
of the circumference, requiring a resection of a PV/
SMV segment of 1.5 2 cm of length. In these cases, 
reconstruction was performed by end to end anastomosis 
with 5/0 polypropylene. One patient presented tumour 
infiltration of approximately 3.5 cm of length, requiring the 
interposition of an expanded PTFE graft and a double 
anastomosis (proximally and distally) (Table III).
Postoperative complications; reinterventions
Global mortality of the series was 1.5%. The VR- group 
presented less complications than the VR+ group, 
but without significant differences (44.8% vs. 55.5%) 
(p=0.582). The Clavien Dindo classification makes it 
possible to group complications according to its severity 
Table II: Demographical data.
Demographical 
data  VR (-) VR (+) p
Age 65 68.9
Women  18/49 (36.8%) 9/18 (50%)
Men 31/49 (63.2%) 9/18 (50%)
ASA I  13/49 (26.5%) 1/18 (5.6%)
ASA II 36/49 (73.59%) 17/18 (94.4%)
0.184
0.403
0.090
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(see Table I). The VR+ group presented a slightly greater 
incidence of severe complications (groups III and IV of 
Clavien’s classification), but again without significant 
differences (VR- group: 14.2%; VR+ group: 16.6%) 
(p=0.582). Most frequent complications were pancreatic 
fistula (7 cases, 10.4%), followed by delayed gastric 
emptying (6 cases, 8.9%), biliary fistula (4 cases, 5.9%), 
abdominal abscess (3 cases, 4.5%) and central catheter 
infection (3 cases, 4.5%). Complications of both groups 
are detailed in tables IV and V. 
The VR+ group also presented a greater incidence 
of reinterventions (11.1%) than the VR- group (8.2%), 
although without significant differences (p=0.666). Table 
VI describes the etiology of surgical reinterventions.
In hospital mortality
Global mortality of the series was 1.5%. No death was 
registered in the VR- group, whereas one death occurred 
in the VR+ group, thus resulting in a 5.5% mortality rate. 
However, the difference when comparing both groups 
(p=0.258) remains non significant. The deceased patient 
was a 76 year old woman with a tumour presenting a large 
infiltration of the mesenteric portal confluence which required 
a venous resection of 3.5 cm of length. An expanded PTFE 
prosthesis was needed for its reconstruction. The patient 
presented an early thrombosis in the graft with shock and 
rapidly progressive multiorgan failure during the immediate 
postoperative period (24 hours).
Hospital stay
Global median hospital stay was 16.1 days, in line with 
most of the series consulted. Paradoxically, the VR- group 
presented a slightly greater median stay as the VR+ 
group (15.2 vs. 16.4 days), although without statistical 
signification (p=0.977).
Readmissions
The VR+ group presented a higher incidence of 
readmissions after hospital discharge than the VR- group 
(11.1% vs. 6.1%) (p=0.590). Reasons for readmissions 
were dehydration, delayed gastric emptying, pneumonia 
and hepatic abscess, and are presented in table VII.
Histopathological results
Of the 18 patients who underwent venous resection, 
72.2% (13 patients) presented histological demonstration 
of vascular infiltration (true venous infiltration) and the 
Table III: Type of venous resection of the mesenteric portal confluence (PV/SMV).
Type of venous resection N (%)
Lateral resection 15/18 (83.5%)
Segmental resection with end to end  2/18 (11%)
anastomosis 
Segmental resection with end to end  1/18 (5.5%)
anastomosis with a PTFE graft 
Table IV: General mortality and morbility.
COMPLICATIONS VR (-) VR (+) P
 N: 49 N: 18
Global Morbidity 33/67 (49.2%)
Morbility 22/49 (44.8%) 10/18 (55.5%) 0.582
III IV Clavien 7/49 (14.2%) 3/18 (16.6%) 1.000
Global mortality 1/67 (1.5%)
Mortality 0/49 1/18 (5.5%) 0.258
Table VI: Etiology of surgical reinterventions.
Reinterventions VR (-) VR (+)
 N: 49 N: 18
Reinterventions 4/49 (8.2%) 2/18 (11.1%) p=0.666
Loop dehiscence 0 1
H J dehiscence 0 1
Intestinal obstruction 1 0
Abdominal abscess 1 0
Pancreatic fistula 1 0
Extravasation of jejunostomy 1 0
Total 4  2
Table VII: Reasons for readmission after hospital discharge
Urgent readmissions VR (-) VR (+)
 N: 49 N: 18
Readmissions 3/49 (6.1%) 2/18 (11.1%) p= 0.590
Delayed gastric emptying 0 1 
Dehydration 1 1 
Pneumonia 1 0 
Hepatic abscess 1 0 
Total 3  2
Table V: Specific complications.
COMPLICATIONS VR (-) VR (+)
 N: 49 N: 18
Pancreatic fistula 5 2
DGE 4 2
Biliary fistula 2 2
Central catheter infection 3 1
Wound infection 3 0
Abdominal abscess 3 0
Intestinal obstruction 1 0
Hepatic abscess 1 0
Respiratory distress 1 0
Subclavian thrombosis 1 0
Upper gastrointestinal bleeding 1 0
Extravasation of jejunostomy 1 0
Urinary infection 1 1
Chylous ascites 0 1
Yeyunal dehiscence 0 1
Pulmonary thromboembolism 0 1
Portal vein thrombosis 0 1
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resting 27.8% (5 patients) presented a non tumoural 
inflammatory desmoplastic reaction on the venous 
wall. As for the histological study, this subgroup of 13 
patients was compared with the other two groups in 
order to avoid bias when comparing patients with venous 
resection but without true venous infiltration. The tumour 
size was similar in the three groups (2.9 vs. 3.1 vs. 3.2 
cm) (p=0.465). As shown in table VIII, there are no 
significant differences when studying the degree of cell 
differentiation among the different groups (p=0.403), with 
very similar percentages of undefined tumours in all three 
groups. Unlike other series consulted, in the present 
study lymph node infiltration was more common in the 
VR- group (77.5 vs. 66.6%), obtaining the same result 
when separately analysing tumours with true venous 
infiltration (76.9 vs. 77.5%), although without a significant 
difference (p=0.424). No differences were found either in 
the number of lymph nodes surgically removed (p=0.857) 
nor in the percentage of tumours with perineural infiltration 
(100 vs. 95.9%) (p=0.523). 
As for the resection margin involvement, patients with 
venous resection and with tumours with a true venous 
infiltration presented a higher incidence of positive 
surgical margins (18.4 vs. 50 vs. 61.5%) (p=0.003). 
Survival results 
The median follow up of all patients was 25.3 months 
(range 4 104). Median survival was similar in both 
VR- and VR+ groups (25.6 and 24.6 months) and 
no significant differences were detected. The survival 
study was completed comparing the two groups of 
study (VR- and VR+) with a third group of patients 
considered unresectable due to infiltration of the 
mesenteric portal confluence who were diagnosed 
before the introduction of the vascular resection 
program. Median survival of these two groups was 
significantly higher than that of unresectable patients. 
Survival of the VR- group was significantly higher than 
that of the group of unresectable patients (25.6 ± 3.6 
vs. 10.6 ± 2.3) (p=0.000). Likewise, survival of the 
VR+ group was significantly higher than that of the 
group of unresectable patients (22.1 ± 4.2 vs. 10.6 ± 
2.3) (p=0.007). An analysis of medium and long term 
survival reveals that these are similar in patients who 
underwent a CPD with and without vascular resection, 
and that this similarity is maintained at 5 years of follow 
up. These figures support the second hypothesis, 
that is, that patients with venous infiltration that allow 
for a vascular resection have a similar survival to those 
without vascular infiltration (Table IX) (Figure 5).
Table VIII: Histological results
HISTOLOGY VR (-) VR (+) True venous infiltration P
 N: 49 N: 18   N: 13
Tumour size 2.9 ± 0.1 3.1 ± 0.2 3,2 ± 0,39 0.465
G1 8/49 (16.3%) 6/18 (33.3%) 3/13 (23.1%)
G2 32/49 (65.3%) 7/18 (38.9%) 7/13 (53.8%) 0.403
G3 9/49 (18.4%) 5/18 (27.8%) 3/13 (23.1%)
Surgically removed lymph nodes (median) 18.2 17.6 19.7 0.857
N0 11/49 (22.4%) 6/18 (33.3%) 3/13 (23.1%)
N1 38/49 (77.6%) 12/18 (66.6%) 10/13 (72.2%) 
Perineural infiltration 47/49 (95.9%) 18/18 (100%) 13/13 (100%) 0.523
Lymphatic vessel infiltration 44/49 (89.8%) 16/18 (88.9%) 11/13 (84.6%) 0.871
R0 margin 40/49 (81.6%) 9/18 (50%) 5/13 (38.5%)
R1 margin 9/49 (18.4%) 9/18 (50%) 8/13 (61.5%)
0.424
0.003
Table IX: Median medium and long term survival
One way ANOVA,  VR+/palliative, p=0.007; VR-/palliative, p=0.000
SURVIVAL VR (-) VR (+) Unresectable patients
Follow up in months (range) 4-104 6-42 2-36
Median survival 25.6 ± 3.6 22.1 ± 4.2 10.6 ± 2.3**,***
 34/44  12/13  
 (77.3%) (92.3%)
 15/44  6/13  
 (34.1%) (46.2%)
 7/44  3/13 
 (15.9%) (23.1%)
 5/44 
 (11.4%)
 5/44
 (11.4%)
1 year 5/22 (22.7%)
5/22 (22.7%)
2/22 (9.1%)
0/23 (0%)1/13 (7.7%)
1/13 (7.7%) 0/23 (0%)
2 years
3 years
4 years
5 years
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However, survival of those patients who did not undergo a 
surgery due to venous infiltration was of 21.7% at 1 year, 
17.4% at 2 years and 4.3% at 3 years. In this group of 
patients, the median survival was significantly smaller (10.6 
months) with no survivors registered at 4 and 5 years. The 
statistical contrast log rank (with a value of 19.918 and a 
degree of freedom 2) gives a p value associated to the 
contrast of 0.000, thus denoting statistically significant 
differences in survival for these groups (Figure 6). 
Discussion
Pancreatic cancer is actually the fourth leading cause of 
cancer deaths in western countries, with an increasing 
incidence over the last two decades due to unknown 
reasons.2,3,30 Despite the development of diagnostic 
imaging, most patients with pancreatic cancer are 
diagnosed when the tumour has already reached an 
advanced stage. At the moment of diagnosis, 50% 
of patients present hepatic, pulmonary or peritoneal 
dissemination, and 25-30% of them have locally advanced 
infiltration of the mesenteric vessels or the celiac trunk. As 
for the prognosis, pancreatic cancer is still the digestive 
cancer with worst prognosis, with a global survival at 5 years 
of 5% and a life expectancy for patients with successfully 
removed tumours of 15-22 months.31,32 Patients whose 
pancreatic cancer is presented with hepatic, pulmonary 
or peritoneal metastases have a survival of 3-6 months, 
whereas those patients with locally advanced tumours 
with infiltration of the mesenteric portal confluence who 
do not undergo vascular resection have an estimated 
survival of 3-12 months.1,33 Despite its poor prognosis, 
resectable patients have the highest life expectancy with 
a survival at 5 years of 25%, explaining the great efforts 
made to increase resectability and survival both from the 
oncological and the surgical point of view.15,31,34 
Prognostic factor
The most important independent factors described in 
long term prognosis for pancreatic cancer are the degree 
of cell differentiation, lymph node affectation, resection 
margin involvement and infiltration of peripancreatic 
nerve plexus.6,31,32,35,36,37 Patients without lymph node 
infiltration have a survival at 1 and 3 years of 85 and 45%, 
respectively, whereas this decreases to 70 and 24% in 
cases of microscopic lymph node infiltration.6,31 
Resection margins
Due to the existing variety in the definitions of tumoural 
infiltration, there is a great divergence in published 
involvement indexes of margin resection.1,2 Until 
recently, criterion by the American Joint Commission on 
Cancer (AJCC) was the most commonly used, staging 
microscopic margin involvement as R1 if the tumour cells 
are present at the line of resection (0 mm). Therefore, 
according to this criterion, tumour resections with a 
margin involvement of 0 1 mm were considered as clear 
margins (Figure 7).
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Figure 5: Actuarial survival of patients with and without venous resection. Figure 6: Actuarial survival of patients with and without venous resection, com-
pared to patients who did not undergo surgery due to venous infiltration.
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Figure 7: Surgical resection margin at <1 mm of the tumour.
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However, in an attempt to decrease the local recurrence 
rate, most reference centres are actually following Verbeke’s 
criteria29, who considers margins as infiltrated if tumour 
cells are at ≤1 mm of the line of resection (Figure 8). This 
shift has very important implications, as the application of 
the ≤1 mm criteria has increased the incidence of positive 
resection margins (R1), with the resulting increase in the 
indication of postoperative radiotherapy.
In Zhang’s study,2 the median survival of patients without 
margin involvement (R0) was 28.7 months, whereas that 
of patients with margin involvement (R1) was 17 months. 
Likewise, survival at 1 and 3 years for R0 patients was of 91 
and 37%, respectively, whereas these figures decreased 
to 37 and 18%, respectively, for R1 patients. When 
surgical resection margins are macroscopically involved 
(R2), survival is practically similar to that of patients who 
do not undergo surgical resection.38 Among the variety 
of resection margins obtained in CPD, the SMA margin 
plays the main role, as this is the most commonly involved 
margin and that most directly related with survival, so it is 
therefore necessary to make an effort to obtain surgical 
margins without tumoral involvement.1,2,29,35,39 Current 
surgical protocols insist on the need of performing a CPD 
with lymphadenectomy and resection of the perineural 
tissue until reaching the right lateral wall of the SMA in order 
to obtain a clear retroperitoneal margin (Figure 9).37,40
Right hepatic artery originating from the superior 
mesenteric artery (anatomical variant). LRV: left renal 
vein; SMA: superior mesenteric artery; RHA: right hepatic 
artery originating from the superior mesenteric artery; PV: 
portal vein; P: Cut pancreas; MBD: Main biliary duct, cut 
and clamped.
In the series of the present study, degree of cell 
differentiation, lymph node affectation and perineural 
infiltration was similar in both groups. However, patients 
requiring a venous resection and patients with true venous 
infiltration presented a significantly greater involvement of 
resection margins. Even though the size of our series is 
still limited, this suggests a greater local aggressivity in 
this group of tumours.
Infiltration of the mesenteric portal confluence 
Due to the close contact between the mesenteric vessels 
and the pancreatic head, and particularly the uncinate 
process, pancreatic cancer frequently infiltrates the 
mesenteric portal confluence (Figure 10). Very often, this 
vascular infiltration takes place on the postero lateral side 
of the vein and can be only evidenced once the surgeon 
has cut the pancreatic neck, thus raising the dilemma of 
whether to perform a vascular resection to obtain a clear 
margin (R0) or to leave a macroscopically positive margin 
(R2), with the consequent survival reduction.2 
This fact, combined with the frequent systemic 
dissemination at the moment of diagnosis, explains 
why surgical resectability of pancreatic cancer has 
been performed in less than 20% of patients in the last 
decades.6,33 
Figure 8: Surgical resection margin at >1 mm of the tumour.
Figure 9: Dissection field after removal of the piece; superior mesenteric artery exposed.
Figure 10: Uncinate process tumour with infiltration of the superior mesenteric 
vein larger than 1 cm of cranio caudal length.
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Traditionally, tumoural infiltration of the mesenteric portal 
confluence has been considered as a contraindication for 
surgical resection of pancreatic tumours. Authors such 
as Moore (1953)12, Asada (1963)13 and Fortner (1973)14 
considered the possibility of performing mesenteric 
vascular resections with the aim of increasing resectability 
and survival of patients with locally advanced pancreatic 
cancer, but had to abandon these radical resections due 
to the high morbility and mortality registered. 
The advances in surgical technique and perioperative 
care and the concentration of this type of complex 
surgery in high volume centres have succeed in reducing 
postoperative mortality below 5% and in improving short 
and long term results in CPD patients.27,33,41 Furthermore, 
this improvement in the results has made it possible to 
approach more complex resections with equal morbility 
and mortality rates.11,19,32,42 Currently, numerous groups 
are publishing results that show that patients undergoing 
a VR+ CPD have a similar survival as patients with 
pancreatic head tumours without venous infiltration, as 
well as a clearly greater survival than patients considered 
as unresectable due to venous infiltration.1,3,6,15,19,35,43,44 
According to these results, clinical guidelines have been 
modified (including those by the National Comprehensive 
Cancer Network, NCCN)1,21,41, thus creating a group of 
patients defined as “borderline” that comprises cases of 
PV/SMV confluence infiltration which allow for a vascular 
resection and reconstruction in order to obtain a clear 
surgical margin (R0), and which make it possible to turn a 
clinical stage with an indication of palliative chemotherapy 
and a survival of 10 12 months to a case of resected 
tumour with greater life expectancy. The possibility of 
performing a pancreaticoduodenectomy with resection of 
the mesenteric portal confluence followed by a vascular 
reconstruction constitutes the difference between 
“borderline” tumours and locally advanced tumors with 
massive infiltration of the mesenteric vessels that do not 
allow for surgical resection.39,41 
Currently, there is an ongoing dispute with respect to 
the infiltration of the mesenteric portal confluence by 
pancreatic tumours: on the one hand, it seems a sign 
of its more aggressive biology32,45 whereas, on the other 
hand, it could be a mere result of the tumour location and 
would therefore not imply a worse prognosis once the 
tumour has been resected.35,42 There is though unanimity 
in finding that tumours with venous infiltration larger than 
3 cm of length or of the entire vein circumference and 
those causing thrombosis or complete venous occlusion 
are associated with a worse tumoral stage and an 
increased index of resection margin involvement, and 
therefore venous resection does not seem to present 
a clear benefit in terms of survival.11,32,33,38 Likewise, 
vascular resection is not recommended in tumours of 
the uncinate process with infiltration of the SMV and its 
tributary branches due to the great difficulty of obtaining a 
secure vascular reconstruction.44,46 
Nowadays, preoperative radiological evaluation makes 
it possible to reliably determine a suspected vascular 
infiltration, and vascular resection is supposed to be 
considered before starting the operation. However, 
and despite the development of diagnostic imaging, 
radiological differentiation between vascular infiltration and 
the inflammatory desmoplastic reaction that characterises 
pancreatic tumours makes it difficult to differentiate them 
even during surgery. In fact, histologically determined 
vascular infiltration widely varies among the different 
series, ranging from 40 to 85% of tumoral infiltration in 
the final histological examination.2,6,35,42,44 In the present 
study, true histological infiltration of the PV wall was 
demonstrated in 72.2% of VR+ patients (Figure 11). 
The “non touch” principle of oncological surgery aims to 
achieve an en bloc resection of the tumour with clear 
resection margins and the minimum handling of tumour 
during dissection. This concept includes the dissection 
of the right SMA wall and the resection of the infiltrated 
vein segment.6,39,47,48 The type of venous resection varies 
depending on the degree of vascular infiltration and 
determines several surgical aspects. It requires a correct 
exposition of the PV/SMV confluence, of the splenic vein 
and of the SMV branches. In addition, the entire root 
of the mesentery and the right colon must be widely 
mobilized. In cases in which a vein segment is removed, 
it is recommended to clamp the SMA during venous 
reconstruction to avoid congestion and edema of the 
small intestine.34,43 It is always recommendable to preserve 
the splenic vein, but its ligation greatly facilitates vascular 
reconstruction and splenic drainage is then maintained 
through the short vessels. In cases where this drainage 
is not suitable, it is necessary to replace the splenic 
vein in the reconstructed mesenteric portal confluence 
by performing an end to side anastomosis.6,19,34 Most 
of the consulted series show longer interventions and 
higher transfusion indexes in VR+ patients. In the present 
Figure 11: Histological preparation showing the infiltration of the tumour on the 
portal vein wall.
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study, venous resection supposed a higher interoperative 
transfusion index but without statistical signification. 
However, median operation time was significantly greater 
in the VR+ group.
Morbility and mortality
Most studies agree that this type of larger vascular 
resections involve a complications rate ranging from 35 
to 60%.4,6,19,36,43 However, when comparing patients who 
underwent a standard CPD, the differences observed 
are non significant. Other studies do describe a higher 
complications rate in the VR+ group.17,49 The last two 
meta analyses, published by Zhou and Yu in 2012 
and 2014, did not find significant morbility and mortality 
differences either.3,16 In the present study, global mortality 
was 49%. The VR+ group presented more complications 
than the VR- group (55.5% vs. 44.8%), but without 
significant differences. Furthermore, the incidence of 
severe complications (groups III and IV of Clavien Dindo 
classification requiring surgical/radiological reintervention) 
is in a low range in relation to the series consulted and 
shows no differences among the two groups studied 
(14.2% for VR- and 16.6% for VR+). No significant 
differences could be found either in the incidence of 
specific postoperative complications. Likewise, the VR+ 
group had a greater index of reinterventions than the 
VR- group, but without statistical significance (11.1% vs. 
8.1%) (p=0,666).
In order to increase the accuracy of the present study, 
operative mortality was defined as that occurring during 
the hospital stay and not only during the first 30 days, as 
complications arising from pancreatic surgery frequently 
extends the hospital stay beyond 30 days. Global 
mortality of the present study was 1.5% (1 patient). The 
only death of this series occurred in the VR+ group and 
it was due to an acute venous thrombosis in the PTFE 
graft. This mortality did not show a significant difference 
with the VR- group, and is comparable to that of other 
series consulted.19,32,33 These results confirm the first 
hypothesis by considering that, with a precise surgical 
technique and increased perioperative care, it is possible 
to perform a pancreaticoduodenectomy with venous 
resection in properly selected patients with a similar morbi 
mortality to that of standard pancreaticoduodenectomy. 
However, the authors are conscious that the sample size 
of the VR+ group is still limited, so results must therefore 
be analysed with caution.
Like in other studies,4,35,42 patients of the present study 
with venous infiltration presented a lymph node affectation 
and a degree of cell differentiation similar to that of the 
group without venous infiltration. Although resection margin 
involvement was greater in the VR+ group, the lymph node 
affectation of the group with true venous infiltration did not 
show significant differences, what leads us to think that 
venous infiltration is mainly due to anatomical factors and 
not a more aggressive biological behaviour.
Survival 
A first meta analysis published by Siriwarna in 200620 did 
not reflect a survival increase of VR+ patients. However, 
two recent meta analysis (Zhou in 2012 and Yu in 2014), 
describe a survival at 2 years similar to that obtained in 
VR- patients, with a survival of 50 65% at 1 year, of 20 
30% at 3 years, and of 13 17% at 5 years.3,16 These 
figures have been confirmed by monocentric studies with 
a high volume of patients.19,33,35,36 Other works such as 
those by Kelly, Zhang and Castleberry,2,35,49 describe a 
smaller survival for VR+ patients. In the present study, 
survival of both groups was similar and comparable to the 
above mentioned series. In addition, the study of short 
and medium term survival (at 1 and at 5 years) did not 
show significant differences. Most authors agree that VR+ 
patients have a significantly greater survival than patients 
who did not undergo surgery due to infiltration of the 
mesenteric portal confluence or than those undergoing a 
palliative bilioenteric bypass.6,11 In the present study, VR+ 
patients presented a median survival of 22.1 months, 
whereas survival of non operated patients due to venous 
infiltration was 10.6 months.
These results confirm the second hypothesis of the 
study and show that patients with local infiltration 
of the mesenteric portal confluence can benefit of 
vascular resection and reconstruction, thus obtaining 
a similar survival as patients undergoing a standard 
pancreaticoduodenectomy without vascular resection. 
In fact, the survival obtained doubles that of patients 
considered as unresectable due to venous infiltration. 
Likewise to postoperative morbi mortality, these figures 
must be analysed with caution, and further work and 
research is needed in this direction with a greater number 
of patients.
Limitations of the study
The first limitation is its retrospective nature, even though 
the analysed data was obtained from a prospective 
registry of consecutive patients. 
The second limitation is the relatively limited sample size 
of the VR+ patients, a problem which seems to occur in 
most of the monocentric studies consulted.
The third limitation is the long duration of the data collection 
period, which has supposed that techniques that were not 
applied at the start (such as extended lymphadenectomy, 
initial dissection of the SMA and enlargement of resection 
margins) were being progressively included. However, 
this reflects the logical evolution of surgery to obtain a 
greater radicality and resectability. 
Conclusions
The results of the present study allow us to obtain several 
conclusions which, in any case, should be analysed with 
caution.
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1. Mesenteric portal venous resection in patients with 
pancreatic cancer can be performed in tumours that 
locally infiltrate the mesenteric portal confluence and 
that allow for a proper vascular reconstruction in order to 
obtain an R0 resection margin. 
2. Patients with local resection of the mesenteric portal 
confluence present a postoperative morbility and mortality 
similar to that of patients undergoing a CPD without 
vascular resection. 
3. Vascular resection combined with CPD makes 
it possible to surgically rescue a group of patients 
considered as unresectable until now. These patients 
present a median and long term survival similar to 
that of VR- patients and significantly greater to that of 
patients who did not undergo surgery. Therefore, tumoral 
infiltration of the mesenteric portal confluence must not 
be considered as a formal contraindication for surgery. 
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